Patent Opposition Database

Hide annotations

No Annotations

Related patent application (please put in national patent application/publication number or PCT application/publication number): AR092151A1
Who filed: CILFA
Country: Argentina
Opposition type: Pre-Grant
Opposition status: Under Examination
Date: 25-08-2015
Patent type: Other

Add an annotation

Where in the document

Click within the document, or manually enter the page number below

10 similar patent oppositions

CILFA opposition, ranibizumab and bevacizumab, (AR092372A1)

Countries: Argentina Date: 2015
CILFA opposition, agomelatine, (AR095152A1)

Countries: Argentina Date: 2015
CILFA opposition, lactoferrin, (AR093894A1)

Countries: Argentina Date: 2015
CILFA opposition, metformin, simvastatin or atorvastatin,benazepril, lisinopril or losartan, aspirin, (AR091739A1)

Countries: Argentina Date: 2015
CILFA opposition, 1 1 -beta-hydroxysteroid dehydrogenase 1 , (AR090999A1)

Countries: Argentina Date: 2015
CILFA opposition, montelukast and levocetirizine, (AR087177A1)

Countries: Argentina Date: 2015
CILFA opposition, tobramycin, (AR092318A1)

Countries: Argentina Date: 2015
CILFA opposition, carvedilol+hydrochlorothiazide, (P990105974)

Countries: Argentina Date: 2002
CILFA opposition, Nadifloxacin, (P990106490)

Countries: Argentina Date: 2002
CILFA opposition, Gamma-aminobutiric acid derivatives including gabapentin , pregabalin, baclofen, (P990102313)

Countries: Argentina Date: 2002